Literature DB >> 20368119

The immune response to rabies virus infection and vaccination.

Nicholas Johnson1, Adam F Cunningham, Anthony R Fooks.   

Abstract

Infection with rabies virus causes encephalitis in humans that has a case fatality rate of almost 100%. This inability to resolve infection is surprising since both pre-exposure vaccination and, if given promptly, post-exposure vaccination is highly effective at preventing encephalitic disease. The principal immunological correlate of protection produced by vaccination is neutralizing antibody. T-helper cells contribute to the development of immunity whereas cytotoxic T cells do not appear to play a role in protection and may actually be detrimental to the host. One reason for a failure to protect in humans may be the poor immunological response the virus provokes, despite the period between exposure to virus and the development of disease being measured in months. Few individuals have measurable neutralizing antibody on presentation with disease, although in many cases this develops as symptoms become more severe. Furthermore, when antibody is detected in serum it rarely appears in cerebrospinal fluid suggesting limited penetration into the CNS, the site where it is most needed. The role of the modest mononuclear cell infiltrate into the brain parenchyma is unclear. Some studies suggest the virus can suppress cell-mediated immunity early during the infection although there is little mechanistic evidence to support this beyond suppression of intracellular interferon production by the viral phosphoprotein. In contrast, levels of antibody in the CNS correlate to the peak virus production within the CNS. Here we review the current understanding of immune responses to rabies infection and vaccination against this disease. This article identifies a need to understand how rabies antigens are initially presented and how this can influence the subsequent development of antibody responses. This could help identify ways in which the response to prophylactic vaccination can be enhanced and how the natural immune response to infection can be boosted to combat neuroinvasion. Crown Copyright 2010. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20368119     DOI: 10.1016/j.vaccine.2010.03.039

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  46 in total

Review 1.  Experimental rabies vaccines for humans.

Authors:  James P McGettigan
Journal:  Expert Rev Vaccines       Date:  2010-10       Impact factor: 5.217

2.  Targeting Vaccine-Induced Extrafollicular Pathway of B Cell Differentiation Improves Rabies Postexposure Prophylaxis.

Authors:  Shannon L Haley; Evgeni P Tzvetkov; Samantha Meuwissen; Joseph R Plummer; James P McGettigan
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

Review 3.  Current Developments and Future Prospects for Plant-Made Biopharmaceuticals Against Rabies.

Authors:  Sergio Rosales-Mendoza
Journal:  Mol Biotechnol       Date:  2015-10       Impact factor: 2.695

4.  Immune response following postexposure rabies prophylaxis.

Authors:  Hasan Tahsin Gozdas
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Variable evolutionary routes to host establishment across repeated rabies virus host shifts among bats.

Authors:  Daniel G Streicker; Sonia M Altizer; Andrés Velasco-Villa; Charles E Rupprecht
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-12       Impact factor: 11.205

6.  Protection of non-human primates against rabies with an adenovirus recombinant vaccine.

Authors:  Z Q Xiang; L Greenberg; H C Ertl; C E Rupprecht
Journal:  Virology       Date:  2014-01-09       Impact factor: 3.616

Review 7.  Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential.

Authors:  M A Altinoz; S Guloksuz; I Elmaci
Journal:  Clin Transl Oncol       Date:  2017-01-16       Impact factor: 3.405

Review 8.  Rhabdoviruses as vectors for vaccines and therapeutics.

Authors:  Gabrielle Scher; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2020-10-29       Impact factor: 7.090

Review 9.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

Review 10.  T-cell-inducing vaccines - what's the future.

Authors:  Sarah C Gilbert
Journal:  Immunology       Date:  2012-01       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.